drugset / Trial / NCT03068910

Hyperandrogenemia and Altered Day-night LH Pulse Patterns

NCT03068910

RandomizedCrossoverQuadruple-blindBasic science

Summary

The purpose of this study is to determine if, in mid- to late pubertal girls with hyperandrogenism, androgen-receptor blockade (spironolactone) improves the ability of progesterone to acutely reduce waking luteinizing hormone pulse frequency (primary endpoint).

Timeline

Start
2016-07-21
Primary completion
2025-10-01
Completion
2025-12-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Spironolactone Small molecule 50 mg Oral
Background Progesterone Other / unclassified 0.8 mg/kg Oral